The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis
JSF-3285 is a promising preclinical candidate for tuberculosis that potently targets the <i>Mycobacterium tuberculosis</i> β-ketoacyl-ACP synthase KasA. In mouse models of acute, sub-acute, chronic, and relapse infection, JSF-3285 offers substantial activity in combination with bedaquiline and pretomanid, which could be applicable for both drug-sensitive and drug-resistant infections.
Authors
- Firat Kaya (ORCID: https://orcid.org/0000-0001-8655-2065)
- Heena Soni (ORCID: https://orcid.org/0009-0003-9727-9334)
- Anil M. Shelke
- Sandeep Tyagi (ORCID: https://orcid.org/0000-0002-6066-5392)
- Joel S. Freundlich (ORCID: https://orcid.org/0000-0002-3411-3455)
- Eric L. Nuermberger (ORCID: https://orcid.org/0000-0003-1440-9889)
- David Alland (ORCID: https://orcid.org/0000-0001-5196-1571)
- Kishor Mane
- Pradeep Kumar (ORCID: https://orcid.org/0000-0002-8320-1494)
- Matthew Zimmerman (ORCID: https://orcid.org/0000-0002-6229-0571)
Institutions
- Rutgers, The State University of New Jersey (US)
- Johns Hopkins University (US)
- Hackensack Meridian Health (US)
- Center for Discovery (US)
- Rutgers New Jersey Medical School (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1128/aac.00130-25
- Citations
- 1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.40